Hartford Small Cap Growth HLS Fund
Schedule of Investments
March 31, 2022 (Unaudited)
March 31, 2022 (Unaudited)
Shares or Principal Amount | Market Value† | ||
COMMON STOCKS - 98.1% | |||
Automobiles & Components - 2.3% | |||
106,235 | Fox Factory Holding Corp.* | $ 10,405,718 | |
128,296 | Patrick Industries, Inc. | 7,736,249 | |
97,377 | Thor Industries, Inc. | 7,663,570 | |
25,805,537 | |||
Banks - 2.9% | |||
605,047 | MGIC Investment Corp. | 8,198,387 | |
176,013 | Synovus Financial Corp. | 8,624,637 | |
102,056 | Triumph Bancorp, Inc.* | 9,595,305 | |
74,249 | Western Alliance Bancorp | 6,149,302 | |
32,567,631 | |||
Capital Goods - 10.4% | |||
133,888 | Altra Industrial Motion Corp. | 5,212,260 | |
116,743 | Applied Industrial Technologies, Inc. | 11,984,836 | |
84,089 | Armstrong World Industries, Inc. | 7,568,851 | |
64,722 | Boise Cascade Co. | 4,496,237 | |
82,397 | Chart Industries, Inc.* | 14,153,333 | |
59,163 | Curtiss-Wright Corp. | 8,883,916 | |
293,080 | Hydrofarm Holdings Group, Inc.* | 4,440,162 | |
104,145 | ITT, Inc. | 7,832,745 | |
95,956 | John Bean Technologies Corp. | 11,367,907 | |
158,506 | SPX Corp.* | 7,831,782 | |
540,742 | WillScot Mobile Mini Holdings Corp.* | 21,159,235 | |
383,991 | Zurn Water Solutions Corp. | 13,593,281 | |
118,524,545 | |||
Commercial & Professional Services - 6.6% | |||
135,316 | ASGN, Inc.* | 15,792,730 | |
45,252 | CACI International, Inc. Class A* | 13,632,618 | |
95,413 | Casella Waste Systems, Inc. Class A* | 8,362,949 | |
56,129 | Clean Harbors, Inc.* | 6,266,242 | |
76,094 | Exponent, Inc. | 8,221,957 | |
93,261 | Insperity, Inc. | 9,365,270 | |
81,729 | Tetra Tech, Inc. | 13,480,381 | |
75,122,147 | |||
Consumer Durables & Apparel - 3.7% | |||
99,696 | Crocs, Inc.* | 7,616,775 | |
25,530 | Deckers Outdoor Corp.* | 6,989,348 | |
88,623 | PVH Corp. | 6,789,408 | |
45,711 | TopBuild Corp.* | 8,291,518 | |
444,535 | Under Armour, Inc. Class C* | 6,916,965 | |
100,499 | YETI Holdings, Inc.* | 6,027,930 | |
42,631,944 | |||
Consumer Services - 5.3% | |||
244,455 | BJ's Restaurants, Inc.* | 6,918,077 | |
48,532 | Churchill Downs, Inc. | 10,763,427 | |
515,277 | GAN Ltd.* | 2,483,635 | |
512,705 | Mister Car Wash, Inc.* | 7,582,907 | |
155,727 | Penn National Gaming, Inc.* | 6,605,939 | |
169,328 | Texas Roadhouse, Inc. Class A | 14,177,833 | |
102,077 | Wingstop, Inc. | 11,978,736 | |
60,510,554 | |||
Diversified Financials - 1.6% | |||
188,172 | OneMain Holdings, Inc. | 8,921,235 | |
129,550 | Stifel Financial Corp. | 8,796,445 | |
17,717,680 | |||
Energy - 2.2% | |||
394,458 | Magnolia Oil & Gas Corp. Class A | 9,328,932 | |
180,212 | Ovintiv, Inc. | 9,744,063 | |
82,501 | PDC Energy, Inc. | 5,996,172 | |
25,069,167 |
Shares or Principal Amount | Market Value† | ||
COMMON STOCKS - 98.1% - (continued) | |||
Food & Staples Retailing - 1.3% | |||
293,446 | Performance Food Group Co.* | $ 14,939,336 | |
Food, Beverage & Tobacco - 3.2% | |||
11,729 | Boston Beer Co., Inc. Class A* | 4,556,365 | |
88,915 | Freshpet, Inc.* | 9,126,236 | |
56,271 | Lancaster Colony Corp. | 8,392,820 | |
176,789 | Simply Good Foods Co.* | 6,709,142 | |
498,931 | Sovos Brands, Inc.* | 7,074,841 | |
35,859,404 | |||
Health Care Equipment & Services - 11.3% | |||
28,077 | Amedisys, Inc.* | 4,837,386 | |
99,209 | AtriCure, Inc.* | 6,515,055 | |
275,045 | Covetrus, Inc.* | 4,618,006 | |
116,576 | Glaukos Corp.* | 6,740,424 | |
134,627 | Globus Medical, Inc. Class A* | 9,932,780 | |
192,465 | Health Catalyst, Inc.* | 5,029,110 | |
83,199 | Inari Medical, Inc.* | 7,541,157 | |
154,954 | Integra LifeSciences Holdings Corp.* | 9,957,344 | |
68,316 | LHC Group, Inc.* | 11,518,078 | |
40,361 | ModivCare, Inc.* | 4,657,256 | |
68,496 | Nevro Corp.* | 4,954,316 | |
105,671 | Omnicell, Inc.* | 13,683,338 | |
253,125 | Owens & Minor, Inc. | 11,142,563 | |
723,378 | R1 RCM, Inc.* | 19,357,595 | |
72,494 | Tandem Diabetes Care, Inc.* | 8,430,327 | |
128,914,735 | |||
Household & Personal Products - 0.5% | |||
357,249 | Beauty Health Co.* | 6,030,363 | |
Insurance - 0.4% | |||
161,827 | James River Group Holdings Ltd. | 4,003,600 | |
Materials - 2.0% | |||
367,236 | Axalta Coating Systems Ltd.* | 9,026,661 | |
82,382 | Ingevity Corp.* | 5,278,215 | |
71,558 | Louisiana-Pacific Corp. | 4,445,183 | |
177,279 | Ranpak Holdings Corp. Class A* | 3,621,810 | |
22,371,869 | |||
Media & Entertainment - 2.3% | |||
218,954 | Bumble, Inc. Class A* | 6,345,287 | |
153,555 | Cardlytics, Inc.* | 8,442,454 | |
121,235 | Ziff Davis, Inc.* | 11,733,123 | |
26,520,864 | |||
Pharmaceuticals, Biotechnology & Life Sciences - 11.5% | |||
325,745 | Aclaris Therapeutics, Inc.* | 5,615,844 | |
249,725 | Akero Therapeutics, Inc.* | 3,543,598 | |
103,404 | ALX Oncology Holdings, Inc.*(1) | 1,747,528 | |
140,793 | Apellis Pharmaceuticals, Inc.* | 7,153,692 | |
43,269 | Arrowhead Pharmaceuticals, Inc.* | 1,989,941 | |
98,859 | Arvinas, Inc.* | 6,653,211 | |
168,164 | Avidity Biosciences, Inc.* | 3,105,989 | |
25,881 | BioAtla, Inc.* | 129,405 | |
36,315 | Biohaven Pharmaceutical Holding Co., Ltd.* | 4,305,869 | |
101,399 | Blueprint Medicines Corp.* | 6,477,368 | |
207,622 | Celldex Therapeutics, Inc.* | 7,071,605 | |
202,964 | Cytokinetics, Inc.* | 7,471,105 | |
47,738 | Fate Therapeutics, Inc.* | 1,850,802 | |
31,315 | Harmony Biosciences Holdings, Inc.* | 1,523,475 | |
385,915 | Heron Therapeutics, Inc.*(1) | 2,207,434 | |
759,985 | ImmunoGen, Inc.* | 3,617,529 | |
60,183 | Intellia Therapeutics, Inc.* | 4,373,499 | |
214,976 | KalVista Pharmaceuticals, Inc.* | 3,168,746 | |
115,093 | Kymera Therapeutics, Inc.* | 4,870,736 |
1 |
Hartford Small Cap Growth HLS Fund
Schedule of Investments – (continued)
March 31, 2022 (Unaudited)
March 31, 2022 (Unaudited)
Shares or Principal Amount | Market Value† | ||
COMMON STOCKS - 98.1% - (continued) | |||
Pharmaceuticals, Biotechnology & Life Sciences - 11.5% - (continued) | |||
32,730 | Mirati Therapeutics, Inc.* | $ 2,691,061 | |
50,928 | Morphic Holding, Inc.* | 2,044,759 | |
172,155 | NanoString Technologies, Inc.* | 5,982,386 | |
154,802 | NeoGenomics, Inc.* | 1,880,844 | |
36,572 | Neurocrine Biosciences, Inc.* | 3,428,625 | |
92,571 | Pacira BioSciences, Inc.* | 7,065,019 | |
172,867 | PTC Therapeutics, Inc.* | 6,449,668 | |
165,650 | Revolution Medicines, Inc.* | 4,225,731 | |
170,569 | Stoke Therapeutics, Inc.* | 3,590,477 | |
254,365 | Syndax Pharmaceuticals, Inc.* | 4,420,864 | |
79,780 | Turning Point Therapeutics, Inc.* | 2,142,093 | |
53,386 | Ultragenyx Pharmaceutical, Inc.* | 3,876,891 | |
18,947 | United Therapeutics Corp.* | 3,399,281 | |
114,215 | Veracyte, Inc.* | 3,148,908 | |
131,223,983 | |||
Real Estate - 5.1% | |||
397,549 | Essential Properties Realty Trust, Inc. REIT | 10,057,990 | |
516,069 | Independence Realty Trust, Inc. REIT | 13,644,865 | |
66,373 | PS Business Parks, Inc. REIT | 11,155,974 | |
157,670 | Rexford Industrial Realty, Inc. REIT | 11,760,605 | |
118,477 | Ryman Hospitality Properties, Inc. REIT* | 10,991,111 | |
57,610,545 | |||
Retailing - 1.4% | |||
159,028 | Ollie's Bargain Outlet Holdings, Inc.* | 6,831,843 | |
97,356 | Shutterstock, Inc. | 9,061,896 | |
15,893,739 | |||
Semiconductors & Semiconductor Equipment - 5.3% | |||
142,336 | Axcelis Technologies, Inc.* | 10,750,638 | |
96,459 | Cirrus Logic, Inc.* | 8,178,759 | |
202,880 | Lattice Semiconductor Corp.* | 12,365,536 | |
31,892 | MKS Instruments, Inc. | 4,783,800 | |
140,539 | Power Integrations, Inc. | 13,025,154 | |
55,112 | Synaptics, Inc.* | 10,994,844 | |
60,098,731 | |||
Software & Services - 15.6% | |||
116,134 | Alarm.com Holdings, Inc.* | 7,718,266 | |
122,697 | Blackbaud, Inc.* | 7,345,869 | |
77,153 | Concentrix Corp. | 12,850,604 | |
79,445 | Consensus Cloud Solutions, Inc.* | 4,777,028 | |
188,089 | Digital Turbine, Inc.* | 8,240,179 | |
132,913 | DigitalOcean Holdings, Inc.* | 7,689,017 | |
83,504 | ExlService Holdings, Inc.* | 11,963,618 | |
40,760 | Five9, Inc.* | 4,499,904 | |
102,877 | LiveRamp Holdings, Inc.* | 3,846,571 | |
72,035 | Manhattan Associates, Inc.* | 9,991,975 | |
385,230 | Olo, Inc. Class A* | 5,104,297 | |
128,631 | Perficient, Inc.* | 14,160,987 | |
87,625 | Q2 Holdings, Inc.* | 5,402,081 | |
127,690 | Rapid7, Inc.* | 14,204,236 | |
473,512 | Repay Holdings Corp.* | 6,993,772 | |
139,453 | Shift4 Payments, Inc. Class A* | 8,636,324 | |
109,201 | Sprout Social, Inc. Class A* | 8,749,184 | |
229,997 | Varonis Systems, Inc.* | 10,934,057 | |
227,434 | Veritone, Inc.*(1) | 4,157,494 | |
775,899 | Verra Mobility Corp.* | 12,631,636 | |
66,735 | Workiva, Inc. Class A* | 7,874,730 | |
177,771,829 |
Shares or Principal Amount | Market Value† | ||
COMMON STOCKS - 98.1% - (continued) | |||
Technology Hardware & Equipment - 3.2% | |||
27,230 | Fabrinet* | $ 2,862,690 | |
184,767 | II-VI, Inc.* | 13,393,760 | |
96,938 | Insight Enterprises, Inc.* | 10,403,386 | |
104,844 | Lumentum Holdings, Inc.* | 10,232,774 | |
36,892,610 | |||
Total Common Stocks (cost $896,166,286) | $ 1,116,080,813 | ||
SHORT-TERM INVESTMENTS - 1.3% | |||
Repurchase Agreements - 0.9% | |||
$ 10,052,973 | Fixed Income Clearing Corp. Repurchase Agreement dated 03/31/2022 at 0.240%, due on 04/01/2022 with a maturity value of $10,053,040; collateralized by U.S. Treasury Note at 2.875%, maturing 05/15/2028, with a market value of $10,254,092 | $ 10,052,973 | |
Securities Lending Collateral - 0.4% | |||
4,386,466 | Goldman Sachs Financial Square Funds, Government Fund, Institutional Class, 0.25%(2) | 4,386,466 | |
524,283 | Invesco Government & Agency Portfolio, Institutional Class, 0.26%(2) | 524,283 | |
4,910,749 | |||
Total Short-Term Investments (cost $14,963,722) | $ 14,963,722 | ||
Total Investments (cost $911,130,008) | 99.4% | $ 1,131,044,535 | |
Other Assets and Liabilities | 0.6% | 7,192,836 | |
Total Net Assets | 100.0% | $ 1,138,237,371 |
Note: | Percentage of investments as shown is the ratio of the total market value to total net assets. |
Equity industry classifications used in this report are the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI, Inc. and Standard & Poor’s. | |
For Fund compliance purposes, the Fund may not use the same classification system. These classifications are used for financial reporting purposes. | |
See “Glossary” for abbreviation descriptions. |
* | Non-income producing. |
(1) | Represents entire or partial securities on loan. |
(2) | Current yield as of period end. |
† | For information regarding the Fund’s significant accounting policies, please refer to the Fund’s most recent shareholder report. |
2 |
Hartford Small Cap Growth HLS Fund
Schedule of Investments – (continued)
March 31, 2022 (Unaudited)
March 31, 2022 (Unaudited)
Fair Value Summary
The following is a summary of the fair valuations according to the inputs used as of March 31, 2022 in valuing the Fund’s investments.
Description | Total | Level 1 | Level 2 | Level 3(1) | ||||
Assets | ||||||||
Common Stocks | ||||||||
Automobiles & Components | $ 25,805,537 | $ 25,805,537 | $ — | $ — | ||||
Banks | 32,567,631 | 32,567,631 | — | — | ||||
Capital Goods | 118,524,545 | 118,524,545 | — | — | ||||
Commercial & Professional Services | 75,122,147 | 75,122,147 | — | — | ||||
Consumer Durables & Apparel | 42,631,944 | 42,631,944 | — | — | ||||
Consumer Services | 60,510,554 | 60,510,554 | — | — | ||||
Diversified Financials | 17,717,680 | 17,717,680 | — | — | ||||
Energy | 25,069,167 | 25,069,167 | — | — | ||||
Food & Staples Retailing | 14,939,336 | 14,939,336 | — | — | ||||
Food, Beverage & Tobacco | 35,859,404 | 35,859,404 | — | — | ||||
Health Care Equipment & Services | 128,914,735 | 128,914,735 | — | — | ||||
Household & Personal Products | 6,030,363 | 6,030,363 | — | — | ||||
Insurance | 4,003,600 | 4,003,600 | — | — | ||||
Materials | 22,371,869 | 22,371,869 | — | — | ||||
Media & Entertainment | 26,520,864 | 26,520,864 | — | — | ||||
Pharmaceuticals, Biotechnology & Life Sciences | 131,223,983 | 131,223,983 | — | — | ||||
Real Estate | 57,610,545 | 57,610,545 | — | — | ||||
Retailing | 15,893,739 | 15,893,739 | — | — | ||||
Semiconductors & Semiconductor Equipment | 60,098,731 | 60,098,731 | — | — | ||||
Software & Services | 177,771,829 | 177,771,829 | — | — | ||||
Technology Hardware & Equipment | 36,892,610 | 36,892,610 | — | — | ||||
Short-Term Investments | 14,963,722 | 4,910,749 | 10,052,973 | — | ||||
Total | $ 1,131,044,535 | $ 1,120,991,562 | $ 10,052,973 | $ — |
(1) | For the period ended March 31, 2022, there were no transfers in and out of Level 3. |
3 |
Hartford HLS Series Fund II, Inc. (the "Company")
GLOSSARY: (abbreviations used in preceding Schedule of Investments)
Other Abbreviations: | |
REIT | Real Estate Investment Trust |
4 |
Hartford HLS Series Fund II, Inc. (the "Company")
Notes to the Schedule of Investments
March 31, 2022 (Unaudited)
March 31, 2022 (Unaudited)
1. | Investment Valuation and Fair Value Measurements: |
For purposes of calculating the net asset value per share ("NAV") of each class of Hartford Small Cap Growth HLS Fund (the "Fund"), portfolio securities and other assets held in the Fund’s portfolio for which market prices are readily available are valued at market value. Market value is generally determined on the basis of official close price or last reported trade price. If no trades were reported, market value is based on prices obtained from a quotation reporting system, established market makers (including evaluated prices), or independent pricing services. Pricing vendors may use matrix pricing or valuation models that utilize certain inputs and assumptions to derive values, including transaction data, credit quality information, general market conditions, news, and other factors and assumptions. | |
If market prices are not readily available or are deemed unreliable, the Fund will use the fair value of the security or other instrument as determined in good faith under policies and procedures established by and under the supervision of the Board of Directors of the Company (the “Board of Directors”) (“Valuation Procedures”). Market prices are considered not readily available where there is an absence of current or reliable market-based data (e.g., trade information or broker quotes), including where events occur after the close of the relevant market, but prior to the NYSE Close, that materially affect the values of the Fund’s portfolio holdings or assets. In addition, market prices are considered not readily available when, due to extraordinary circumstances, the exchanges or markets on which the securities or other instruments trade do not open for trading for the entire day and no other market prices are available. Fair value pricing is subjective in nature and the use of fair value pricing by the Fund may cause the NAV of its shares to differ significantly from the NAV that would have been calculated using market prices at the close of the exchange on which a portfolio holding is primarily traded. There can be no assurance that the Fund could obtain the fair value assigned to an investment if the Fund were to sell the investment at approximately the time at which the Fund determines its NAV. | |
Prices of foreign equities that are principally traded on certain foreign markets will generally be adjusted daily pursuant to a fair value pricing service in order to reflect an adjustment for the factors occurring after the close of certain foreign markets but before the NYSE Close. Securities and other instruments that are primarily traded on foreign markets may trade on days that are not business days of the Fund. The value of the foreign securities or other instruments in which the Fund invests may change on days when a shareholder will not be able to purchase or redeem shares of the Fund. | |
Fixed income investments (other than short-term obligations) held by the Fund are normally valued at prices supplied by independent pricing services in accordance with the Valuation Procedures. Short-term investments maturing in 60 days or less are generally valued at amortized cost. | |
Exchange-traded derivatives, such as options, futures and options on futures, are valued at the last sale price determined by the exchange where such instruments principally trade as of the close of such exchange (“Exchange Close”). If a last sale price is not available, the value will be the mean of the most recently quoted bid and ask prices as of the Exchange Close. If a mean of the bid and ask prices cannot be calculated for the day, the value will be the most recently quoted bid price as of the Exchange Close. Over-the-counter derivatives are normally valued based on prices supplied by independent pricing services in accordance with the Valuation Procedures. | |
Investments valued in currencies other than U.S. dollars are converted to U.S. dollars using the prevailing spot currency exchange rates obtained from independent pricing services for calculation of the NAV. As a result, the NAV of the Fund’s shares may be affected by changes in the value of currencies in relation to the U.S. dollar. The value of securities or other instruments traded in markets outside the United States or denominated in currencies other than the U.S. dollar may be affected significantly on a day that the Exchange is closed and the market value may change on days when an investor is not able to purchase, redeem or exchange shares of the Fund. | |
Foreign currency contracts represent agreements to exchange currencies on specific future dates at predetermined rates. Foreign currency contracts are valued using foreign currency exchange rates and forward rates as provided by an independent pricing service on the Valuation Date. | |
Investments in open-end mutual funds, if any, are valued at the respective NAV of each open-end mutual fund on the Valuation Date. Shares of investment companies listed and traded on an exchange are valued in the same manner as any exchange-listed equity security. Such open-end mutual funds and listed investment companies may use fair value pricing as disclosed in their prospectuses. | |
Financial instruments for which prices are not available from an independent pricing service may be valued using market quotations obtained from one or more dealers that make markets in the respective financial instrument in accordance with the Valuation Procedures. | |
U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) defines fair value as the price that the Fund would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants. The U.S. GAAP fair value measurement standards require disclosure of a fair value hierarchy for each major category of assets and liabilities. Various inputs are used in determining the fair value of the Fund’s investments. These inputs are summarized into three broad hierarchy levels. This hierarchy is based on whether the valuation inputs are observable or unobservable. |
5 |
Hartford HLS Series Fund II, Inc. (the "Company")
Notes to the Schedule of Investments – (continued)
March 31, 2022 (Unaudited)
March 31, 2022 (Unaudited)
These levels are: |
• | Level 1 – Quoted prices in active markets for identical investments. Level 1 may include exchange-traded instruments, such as domestic equities, some foreign equities, options, futures, mutual funds, exchange traded funds, rights and warrants. |
• | Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar investments; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 2 may include debt investments that are traded less frequently than exchange-traded instruments and which are valued using independent pricing services; foreign equities, which are principally traded on certain foreign markets and are adjusted daily pursuant to a fair value pricing service in order to reflect an adjustment for the factors occurring after the close of certain foreign markets but before the NYSE Close; senior floating rate interests, which are valued using an aggregate of dealer bids; short-term investments, which are valued at amortized cost; and swaps, which are valued based upon the terms of each swap contract. |
• | Level 3 – Significant unobservable inputs that are supported by limited or no market activity. Level 3 may include financial instruments whose values are determined using indicative market quotes or require significant management judgment or estimation. These unobservable valuation inputs may include estimates for current yields, maturity/duration, prepayment speed, and indicative market quotes for comparable investments along with other assumptions relating to credit quality, collateral value, complexity of the investment structure, general market conditions and liquidity. This category may include investments where trading has been halted or there are certain restrictions on trading. While these investments are priced using unobservable inputs, the valuation of these investments reflects the best available data and management believes the prices are a reasonable representation of exit price. |
The Board of Directors has delegated the day-to-day responsibility for implementing the Valuation Procedures to the Valuation Committee. The Valuation Committee will consider all relevant factors in determining an investment’s fair value, and may seek the advice of such Fund’s sub-advisers, knowledgeable brokers, and legal counsel in making such determination. The Valuation Committee reports to the Audit Committee of the Board of Directors.
Valuation levels are not necessarily indicative of the risk associated with investing in such investments. Individual investments within any of the above mentioned asset classes may be assigned a different hierarchical level than those presented above, as individual circumstances dictate.
For additional information, refer to the Fair Value Summary and the Level 3 roll-forward reconciliation, if applicable, which follows the Fund’s Schedule of Investments.
For information regarding the Fund’s other significant accounting policies, please refer to the Fund’s most recent Semi-Annual or Annual Report.
6 |